Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biosimilar Trends Report

EU flag

Sandoz files for approval of Neulasta biosimilar in Europe

Amgen facing increasing competition in global biosimilar market

- PMLiVE

Lantus sales decline as competition heats up at Sanofi

Brand affected by biosimilars, growth of other new drugs and pricing pressure

- PMLiVE

FDA panel recommends first biosimilar antibody for approval

Pfizer to sell Celltrion's infliximab in the US pending FDA approval

National Institute for Health and Care Excellence NICE logo

NICE backs Repatha but rejects cholesterol rival Praluent

New draft guidance marks a U-turn on Amgen's drug but knocks back Sanofi treatment

- PMLiVE

Mylan buys into six biosimilars, including Orencia candidate

Deal with Momenta bolsters biosimilars pipeline for new products

Biosimilars in 2018: EU doctors’ perceptions of RA drug market

Published in pharmaphorum October 2015 by Laurent Chanroux

Research Partnership

Sanofi reception

Sanofi uses priority review voucher for diabetes combo

LixiLan in race with Xultophy in bid to hit US market first

- PMLiVE

Boehringer plans €500m biopharma expansion in Austria

New production facility in Vienna will create 400 jobs when it comes online in 2021

Eli Lilly HQ

Lilly’s Lantus ‘follow-on’ approved in the US

Basaglar is first insulin product to be licensed via the FDA's truncated 505(b)(2) pathway

- PMLiVE

Amgen buys back product rights from GSK

Prolia, Xgeva and Vectibix brought back in-house

EU flag

Second biosimilar anti-TNF nears EU market

SamsungBioepis' version of Enbrel recommended for approval by the CHMP

- PMLiVE

Amgen’s Kyprolis approved in Europe

Multiple myeloma drugwins licence three years after gaining US approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links